Press Releases and Blog
Blog
New Legislation Aims to Increase Competition in U.S. Biosimilar Market
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market. Bringing more biosimilars to market, over time, will allow PBMs to more effectively
Eliminating Spread Pricing Would Lead to Higher Costs and Fewer Choices for America’s Employers
What is spread pricing? Spread pricing is a contract option for employers and plan sponsors who want their pharmacy benefit company to carry the risk that pharmacies
Misguided Legislation Puts Innovation and Savings Delivered by Pharmacy Benefit Industry at Risk
In case you missed it, PCMA President and CEO JC Scott joined Prime Therapeutics’ webinar Beyond the Script: PBM Hot Topics in D.C. to discuss how
Big Pharma Returns with Self-Serving Policies Already Rejected by Congress
While Big Pharma pushes misguided policies targeting pharmacy benefits as part of a blame game designed to keep prescription drug prices high, former Members of
A World Without Pharmacy Benefit Companies? Ask the Department of Labor
The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health
Robust U.S. Biosimilar Market Will Encourage Competition and Lower Prescription Drug Costs for Patients
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play
Press Releases
PCMA Statement on the 2023 Medicare Part D Proposed Rule
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the 2023 Medicare Part D proposed rule
PCMA Welcomes New Policy Legal and State Affairs Additions Announces New Roles
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is announcing the additions of Angela Banks as Vice President, Policy; Jonathan Buxton as Director, State
PCMA Launches New Ad Campaign on Pharma Industry Attempts to Deflect Blame for High Prescription Drug Costs
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA), today, is announcing a new ad campaign, “Drug Manufacturers are Pointing Fingers…Again.” With Congress poised to permanently
PCMA Statement on New White Paper “Assessment of Barriers to Fair Access” Issued by ICER
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on a new white paper issued by the Institute
New Report: Anti-Competitive Practices Lead to High Prescription Drug Costs
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new report, “Drug Manufacturer Strategies for Keeping Drug Costs High,” on pharmaceutical industry pricing tactics
PCMA Statement on Passage of the Bipartisan Infrastructure Package
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on Congress’ passage of the Bipartisan Infrastructure Package:
Policymakers, Drug Pricing and Economic Experts Highlight Importance of Greater Competition to Lower Drug Prices
Conversation on “Improving Competition to Lower Drug Prices” Emphasizes Need to Stop Abuse of the Patent System Last week, The Hill hosted an event titled, “Prescription for Change:
Legislation Targeting REMS Abuse Adds to Bipartisan Action on Solutions to Boost Competition and Lower Prescription Drug Costs
Lawmakers Reintroduce Bill to Close Loopholes Allowing Big Drug Companies to Block Competition from More Affordable Options The Pharmaceutical Care Management Association, PCMA, applauds Senators
Pharma Boardroom: Washington Must Remain Focused on Root Cause of High Drug Prices
For millions of Americans, the prescription drug delivery system works: people, for the most part, can access the medications they need when they need them,
ICYMI: Webinar Highlights How Introduction of More Biosimilars to U.S. Market Will Encourage Competition and Lower Prescription Drug Costs
New Paper Finds Potential Cost Savings from Adalimumab Biosimilars are Significant but Competitive Market Will Take Time The Pharmaceutical Care Management Association (PCMA) agrees that
ICYMI: Economic Experts Agree Anti-Competitive S. 127 Would Increase Rx Drug Costs and Give FTC Unprecedented Authority to Pick Winners and Losers
Misguided Legislation Targets Pharmacy Benefits That Save Employers and Patients an Average of $1,000 Per Person Each Year and Undermines Market Forces in Health Care
What They Are Saying: Lawmakers, Health Care Experts, and Drug Pricing Advocates Support Competition and End to Patent Abuse
Lawmakers, health care experts, and drug pricing advocates agree that big drug companies block competition, are responsible for setting and increasing prices, and must be
ICYMI: Health Care Economist Estimates S.127 Would Increase Federal Deficit by “Tens of Billions of Dollars”
Casey Mulligan, Ph.D., professor of economics at the University of Chicago, member of the National Bureau of Economic Research (NBER), and former Chief Economist of the White House Council of Economic Advisers, testified before the U.S. Senate Committee on Commerce, Science, and Transportation during a hearing Thursday on S. 127.
ICYMI: PCMA Releases Policy Roadmap to Unlock an Affordable Health Care Future for Patients
Pharmacy Benefit Companies Ready to Work with Policymakers on Solutions to Build a More Competitive, Sustainable, and Affordable Prescription Drug Marketplace
ICYMI: New Report Shows Cost of Big Drug Companies’ Patent Abuse, Advocates for a More Affordable Market Call for Solutions to Increase Competition
Study Finds Yearly Cost of Patent Thickets on Five Top-Selling Brand Name Drugs Ranges from $1.8 to $7.6 Billion.
What the Inflation Reduction Act means for PBMs
The Pharmaceutical Care Management Association, which represents PBMs, praised the law for postponing the rebate rule, but once again passed off blame for high drug prices to pharmaceutical companies and health insurers. “The sad reality is that, rather than focus on how to ensure every American can access affordable coverage and high-quality healthcare, the finger pointing is in full swing in Washington with big pharma blaming PBMs and insurers for prices only they can set,” a spokesperson wrote in an email.
